New pill tested to boost cancer immunotherapy
NCT ID NCT06362369
Summary
This study is testing a new oral medication called Alintegimod, given alongside the immunotherapy drugs ipilimumab and nivolumab. It aims to see if this combination is safe and can help control advanced cancers that have spread or returned after other treatments. The study will enroll adults with several types of advanced solid tumors, including melanoma, kidney cancer, and lung cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brown University Health Cancer Institute
RECRUITINGProvidence, Rhode Island, 02906, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Dartmouth Hitchcock
RECRUITINGLebanon, New Hampshire, 03756, United States
Contact
Contact Phone: •••-•••-••••
-
Florida Cancer Specialists
RECRUITINGLake Mary, Florida, 32746, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.